Crossmark

Neighborhood social fragmentation in relation to impaired mismatch negativity among youth at clinical high risk for psychosis and healthy comparisons

Crossref DOI link: https://doi.org/10.1038/s41386-025-02093-4

Published Online: 2025-04-02

Published Print: 2025-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ku, Benson S. https://orcid.org/0000-0001-6994-8770
Hamilton, Holly

Yuan, Qingyue

Parker, David A. https://orcid.org/0000-0002-0240-4741
Roach, Brian J.

Bachman, Peter M.

Belger, Aysenil

Carrión, Ricardo E.

Duncan, Erica

Johannesen, Jason K.

Light, Gregory A.

Niznikiewicz, Margaret A.

Addington, Jean https://orcid.org/0000-0002-8298-0756
Bearden, Carrie E. https://orcid.org/0000-0002-8516-923X
Cadenhead, Kristin S. https://orcid.org/0000-0002-5952-4605
Cannon, Tyrone D. https://orcid.org/0000-0002-5632-3154
Cornblatt, Barbara A.

Keshavan, Matcheri https://orcid.org/0000-0002-5945-888X
Perkins, Diana O.

Stone, William

Woods, Scott W. https://orcid.org/0000-0002-3103-5228
Walker, Elaine

Mathalon, Daniel H. https://orcid.org/0000-0001-6090-4974
Funding

Funding for this research was provided by:

U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (K23 MH129684, U01 MH066134, P50 MH066286, U01 MH081944, U01 MH081902, U01 MH081857, R01 U01 MH066069, U01 MH82022, U01 MH081988, R01 MH076989)
License Information

Text and Data Mining valid from 2025-04-02

Version of Record valid from 2025-04-02
More Information

Article History

Received: 20 December 2024

Revised: 5 March 2025

Accepted: 14 March 2025

First Online: 2 April 2025

Competing interests

: TDC has served as a consultant for Boehringer-Ingelheim Pharmaceuticals and Lundbeck A/S. DOP has served as a consultant for Sunovion and Alkermes, has received research support from Boehringer-Ingelheim, and has received royalties from American Psychiatric Association Publishing. SWW has received investigator-initiated research support from Pfizer and sponsor-initiated research support from Auspex and Teva; he has served as a consultant for Biomedisyn (unpaid), Boehringer-Ingelheim, and Merck and as an unpaid consultant to DSM-5; he has been granted a patent for a method of treating prodromal schizophrenia with glycine; and he has received royalties from Oxford University Press. ED has received research support for work unrelated to this project from Posit Science Inc, Auspex Pharmaceuticals, Teva Pharmaceuticals, and GrayMatters Health. The other authors report no financial relationships with commercial interests.

Document is current

Any future updates will be listed below